Switzerland-based Enhance-D develops a digital health platform for enhancing diabetes and exercise management. It designed its platform to empower people with diabetes through cutting-edge technologies and personalized solutions.
Ireland-based Innovation Zed develops insulin dosing technology, including the InsulCheck DOSE add-on device for pen injectors. The company featured on our 2023 list of drug delivery innovations you should know.
Through their partnership, the two companies aim to integrate Innovation Zed’s DOSE technology into the Enhance-D platform. DOSE, the company’s third-generation technology (marketed as InsulCheck) captures and stores insulin injection data.
“We are very happy to collaborate with the team behind Enhance-D and advance our shared commitment to improve diabetes management,” said Dr. Dean Minnock, CEO of Innovation Zed. “By integrating our InsulCheck DOSE technology into Enhance-D’s innovative platform, we aim to empower users and their caregivers with real-time data and personalized support around exercise, ultimately improving their quality of life.”
Innovation Zed says Enhance-D’s goals of redefining diabetes care align seamlessly with its vision of leveraging technology to enhance patient outcomes.
“This partnership with Innovation Zed represents a significant moment for us at Enhance-D,” CEO Federico Fontana said. “It’s more than just a collaboration; it’s a shared vision to revolutionize diabetes management around exercise by harnessing the power of integrated technologies. Through our combined efforts, we are working for a future where managing exercise and diabetes is more intuitive, efficient, and aligned with our users’ lifestyles.”
